Outpatient Monitoring and Treatment of Chronic Heart Failure Guided by Amino-Terminal Pro-B-Type Natriuretic Peptide Measurement

American Journal of Cardiology

Volumn 101, Issue 3 SUPPL., 2008, Pages

  Troughton, Richard W ^a   Richards, A Mark ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; METOPROLOL; SPIRONOLACTONE; VASODILATOR AGENT;

ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL ASSESSMENT; CLINICAL TRIAL; DRUG MEGADOSE; EXERCISE; FOLLOW UP; HAZARD ASSESSMENT; HEART FAILURE; HUMAN; OUTPATIENT; PATIENT MONITORING; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT OUTCOME;

AMBULATORY CARE; BIOLOGICAL MARKERS; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; OUTPATIENTS; PEPTIDE FRAGMENTS; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; PROTEIN PRECURSORS;

EID: 38649087955     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.11.027     Document Type: Article

References (37)

1. Bettencourt P., Frioes F., Azevedo A., Dias P., Pimenta J., Rocha-Goncalves F., and Ferreira A. Prognostic information provided by serial measurements of brain natriuretic peptide in heart failure. Int J Cardiol 93 (2004) 45-48
2. Gardner R.S., Chong K.S., Morton J.J., and McDonagh T.A. A change in N-terminal pro-brain natriuretic peptide is predictive of outcome in patients with advanced heart failure. Eur J Heart Fail 9 (2007) 266-271
3. Latini R., Masson S., Wong M., Barlera S., Carretta E., Staszewsky L., Vago T., Maggioni A.P., Anand I.S., Tan L.B., Tognoni G., and Cohn J.N. Incremental prognostic value of changes in B-type natriuretic peptide in heart failure. Am J Med 119 (2006) 70.e23-70.e30
4. Wu A.H. Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results. Am Heart J 152 (2006) 828-834
5. Braunschweig F., Fahrleitner-Pammer A., Mangiavacchi M., Ghio S., Fotuhi P., Hoppe U.C., and Linde C. Correlation between serial measurements of N-terminal pro brain natriuretic peptide and ambulatory cardiac filling pressures in outpatients with chronic heart failure. Eur J Heart Fail 8 (2006) 797-803
6. Luthje L., Vollmann D., Drescher T., Schott P., Zenker D., Hasenfubeta G., and Unterberg C. Intrathoracic impedance monitoring to detect chronic heart failure deterioration: relationship to changes in NT-proBNP. Eur J Heart Fail 9 (2007) 716-722
7. Lam C.S., Burnett Jr. J.C., Costello-Boerrigter L., Rodeheffer R.J., and Redfield M.M. Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population. J Am Coll Cardiol 49 (2007) 1193-1202
8. Schou M., Gustafsson F., Kjaer A., and Hildebrandt P.R. Long-term clinical variation of NT-proBNP in stable chronic heart failure patients. Eur Heart J 28 (2007) 177-182
9. Schou M., Gustafsson F., Nielsen P.H., Madsen L.H., Kjaer A., and Hildebrandt P.R. Unexplained week-to-week variation in BNP and NT-proBNP is low in chronic heart failure patients during steady state. Eur J Heart Fail 9 (2007) 68-74
10. Araujo J.P., Azevedo A., Lourenco P., Rocha-Goncalves F., Ferreira A., and Bettencourt P. Intraindividual variation of amino-terminal pro-B-type natriuretic peptide levels in patients with stable heart failure. Am J Cardiol 98 (2006) 1248-1250
11. Hartmann F., Packer M., Coats A.J., Fowler M.B., Krum H., Mohacsi P., Rouleau J.L., Tendera M., Castaigne A., Trawinski J., et al. NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy. Eur J Heart Fail 6 (2004) 343-350
12. Murdoch D.R., McDonagh T.A., Byrne J., Blue L., Farmer R., Morton J.J., and Dargie H.J. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J 138 (1999) 1126-1132
13. Anand I.S., Fisher L.D., Chiang Y.T., Latini R., Masson S., Maggioni A.P., Glazer R.D., Tognoni G., and Cohn J.N. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107 (2003) 1278-1283
14. Richards A.M., Doughty R., Nicholls M.G., Macmahon S., Ikram H., Sharpe N., Espiner E.A., Frampton C., Yandle T.G., and Australia-New Zealand Heart Failure Group. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Circulation 99 (1999) 786-792
15. Troughton R.W., Frampton C.M., Yandle T.G., Espiner E.A., Nicholls M.G., and Richards A.M. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355 (2000) 1126-1130
16. Yoshimura M., Yasue H., Tanaka H., Kikuta K., Sumida H., Kato H., Jougasaki M., and Nakao K. Responses of plasma concentrations of A type natriuretic peptide and B type natriuretic peptide to alacepril, an angiotensin-converting enzyme inhibitor, in patients with congestive heart failure. Br Heart J 72 (1994) 528-533
17. Berry C., Murphy N., De Vito G., Galloway S., Seed A., Fisher C., Sattar N., Vallance P., Hillis W.S., and McMurray J. Effects of aldosterone receptor blockade in patients with mild-moderate heart failure taking a beta-blocker. Eur J Heart Fail 9 (2007) 429-434
18. Feola M., Menardi E., Ribichini F., Vado A., Deorsola A., Ferrero V., Visconti G., Milanese U., and Uslenghi E. Effects of the addition of a low dose of spironolactone on brain natriuretic peptide plasma level and cardiopulmonary function in patients with moderate congestive heart failure. Med Sci Monit 9 (2003) CR341-CR345
19. Macdonald J.E., Kennedy N., and Struthers A.D. Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment. Heart 90 (2004) 765-770
20. Ogawa S., Takeuchi K., Mori T., Nako K., and Ito S. Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor. Clin Exp Pharmacol Physiol 33 (2006) 477-479
21. Rousseau M.F., Gurne O., Duprez D., Van Mieghem W., Robert A., Ahn S., Galanti L., and Ketelslegers J.M. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy. J Am Coll Cardiol 40 (2002) 1596-1601
22. Davis M.E., Richards A.M., Nicholls M.G., Yandle T.G., Frampton C.M., and Troughton R.W. Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure. Circulation 113 (2006) 977-985
23. The RESOLVD Investigators. Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: the Randomized Evaluation of Strategies for Left Ventricular Dysfunction pilot study. Circulation 101 (2000) 378-384
24. Stanek B., Frey B., Hulsmann M., Berger R., Sturm B., Strametz-Juranek J., Bergler-Klein J., Moser P., Bojic A., Hartter E., and Pacher R. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 38 (2001) 436-442
25. Doughty R.N., Whalley G.A., Walsh H.A., Gamble G.D., Lopez-Sendon J., and Sharpe N. Effects of carvedilol on left ventricular remodeling after acute myocardial infarction: the CAPRICORN Echo Substudy. Circulation 109 (2004) 201-206
26. Sanderson J.E., Chan W.W., Hung Y.T., Chan S.K., Shum I.O., Raymond K., and Woo K.S. Effect of low dose beta blockers on atrial and ventricular (B type) natriuretic factor in heart failure: a double blind, randomised comparison of metoprolol and a third generation vasodilating beta blocker. Br Heart J 74 (1995) 502-507
27. Conraads V.M., Beckers P., Vaes J., Martin M., Van Hoof V., De Maeyer C., Possemiers N., Wuyts F.L., and Vrints C.J. Combined endurance/resistance training reduces NT-proBNP levels in patients with chronic heart failure. Eur Heart J 25 (2004) 1797-1805
28. Kruger S., Graf J., Merx M.W., Stickel T., Kunz D., Hanrath P., and Janssens U. Brain natriuretic peptide kinetics during dynamic exercise in patients with chronic heart failure. Int J Cardiol 95 (2004) 49-54
29. Passino C., Severino S., Poletti R., Piepoli M.F., Mammini C., Clerico A., Gabutti A., Nassi G., and Emdin M. Aerobic training decreases B-type natriuretic peptide expression and adrenergic activation in patients with heart failure. J Am Coll Cardiol 47 (2006) 1835-1839
30. Yeh G.Y., Wood M.J., Lorell B.H., Stevenson L.W., Eisenberg D.M., Wayne P.M., Goldberger A.L., Davis R.B., and Phillips R.S. Effects of tai chi mind-body movement therapy on functional status and exercise capacity in patients with chronic heart failure: a randomized controlled trial. Am J Med 117 (2004) 541-548
31. Fruhwald F.M., Fahrleitner-Pammer A., Berger R., Leyva F., Freemantle N., Erdmann E., Gras D., Kappenberger L., Tavazzi L., Daubert J.C., and Cleland J.G. Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony. Eur Heart J 28 (2007) 1592-1597
32. Richards A.M., Doughty R., Nicholls M.G., MacMahon S., Sharpe N., Murphy J., Espiner E.A., Frampton C., Yandle T.G., and Australia-New Zealand Heart Failure Group. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. J Am Coll Cardiol 37 (2001) 1781-1787
33. Hartmann F., Packer M., Coats A.J., Fowler M.B., Krum H., Mohacsi P., Rouleau J.L., Tendera M., Castaigne A., Anker S.D., et al. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation 110 (2004) 1780-1786
34. Jourdain P., Jondeau G., Funck F., Gueffet P., Le Helloco A., Dsonal E., Aupetit J.F., Aumont M.C., Galinier M., Eicher J.C., Cohen-Solal A., and Juilliere Y. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 49 (2007) 1733-1739
35. Shah M.R., Claise K.A., Bowers M.T., Bhapkar M., Little J., Nohria A., Gaulden L.H., McKee V.K., Cozart K.L., Mancinelli K.L., et al. Testing new targets of therapy in advanced heart failure: the design and rationale of the Strategies for Tailoring Advanced Heart Failure Regimens in the Outpatient Setting. BRain NatrIuretic Peptide Versus the Clinical CongesTion ScorE (STARBRITE) trial. Am Heart J 150 (2005) 893-898
36. Lainchbury J.G., Troughton R.W., Frampton C.M., Yandle T.G., Hamid A., Nicholls M.G., and Richards A.M. NTproBNP-guided drug treatment for chronic heart failure: design and methods in the "BATTLESCARRED" trial. Eur J Heart Fail 8 (2006) 532-538
37. Brunner-La Rocca H.P., Buser P.T., Schindler R., Bernheim A., Rickenbacher P., and Pfisterer M. Management of elderly patients with congestive heart failure-design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). Am Heart J 151 (2006) 949-955